KB-0742 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Part 1: Dose Escalation. The primary objective of Part 1 of this study is to evaluate the safety and tolerability of KB-0742 in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability of KB-0742 in defined participant cohorts including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC).
Are You a Good Fit for This Trial?
Adults and teens from age 12 with certain advanced cancers (like lung, breast, ovarian cancer, or non-Hodgkin lymphoma) that have come back or didn't respond to treatment can join. They must be healthy enough for daily activities (ECOG PS 0-1), have a tumor that can be measured, recovered from past treatments' side effects, not pregnant/breastfeeding, and agree to use birth control.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Sequential cohorts of participants will receive escalating doses of KB-0742 to evaluate safety and tolerability
Cohort Expansion
Further evaluation of safety and tolerability of KB-0742 in defined participant cohorts
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- KB-0742
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kronos Bio
Lead Sponsor